Search results
Better Dividend Stock: Pfizer vs. AbbVie
Motley Fool via Yahoo Finance· 4 months agoIncome-seeking investors usually don't think of the innovation-dependent pharmaceutical industry as a place to look for businesses with reliable cash...
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
Zacks via Yahoo Finance· 3 months agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is...
Is AbbVie a Good Dividend Stock to Buy on the Dip?
Motley Fool· 1 year agoThe week that ended Jan. 13 was a relatively good one for the stock market overall. Is AbbVie's recent dip the first of many, or could it be an...
3 Spectacular High-Yield Dividend Stocks to Buy in November
Motley Fool· 7 months agoNot all dividend stocks are in the same league. Here's why they view drugmakers AbbVie (NYSE: ABBV),...
Top Dividend Stocks: Leading Biotech AbbVie Hikes Payout
Investor's Business Daily· 1 year agoIBD's Income Investor column highlights top dividend stocks. With a long track record of dividend...
Dividend Capture Strategy: 10 High Yield Stocks To Buy in November
Insider Monkey via Yahoo Finance· 7 months agoIn this article, we discuss dividend capture strategy and high yield stocks to buy in November. You...
Want to Retire Early? These 5 Ultra-High-Yield Dividend Stocks Can Help
Motley Fool· 2 years agoBuying dividend stocks, which make so much money that they give a chunk of their profits on a...
1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever
Motley Fool· 11 months agoHere's one phenomenal high-yield dividend stock you can buy and hold forever. The company has raised...
AbbVie Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance· 5 months agoAbbVie Inc (NYSE:ABBV) recently announced a dividend of $1.55 per share, payable on 2024-02-15, with the ex-dividend date set for 2024-01-12. As...
Is AbbVie Still a Good Dividend Stock to Buy?
Motley Fool· 7 months agoUnfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S....
